Activation of the receptor, programmed death 1 (PD-1), has been found to inhibit immune control of tumor growth, with the PD-1 ligand, PD-L1, being significantly upregulated in solid tumors like CRC (Hino et al. 2010). This evidence concerns the gene CD274 and neoplasm.